<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370629</url>
  </required_header>
  <id_info>
    <org_study_id>6621-049</org_study_id>
    <secondary_id>EP01029.004</secondary_id>
    <nct_id>NCT01370629</nct_id>
  </id_info>
  <brief_title>Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)</brief_title>
  <official_title>A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiome Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiome Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional prospective study is a post-authorization safety study (PASS) of
      vernakalant conducted to collect information about normal conditions of use and appropriate
      dosing, and to quantify possible medically significant risks associated with the use of
      vernakalant in real-world clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 8, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing significant hypotension</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant ventricular arrhythmia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant atrial flutter</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant bradycardia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who are converted to sinus rhythm for at least one minute</measure>
    <time_frame>Up to 90 minutes after the start (baseline) of first infusion of vernakalant</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2013</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vernakalant</intervention_name>
    <description>Prescribed at the discretion of the physician in accordance with their usual practice</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>BRINAVESSÂ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants treated with intravenous vernakalant in acute care and inpatient hospital
        settings per usual care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be treated with intravenous vernakalant, independently of this study

          -  Participant and/or legal guardians willing to provide informed consent and/or informed
             assent according to local regulations

        Exclusion Criteria:

        - Enrollment in an investigational drug or device clinical trial in the 30 days prior to
        study enrolment. Participation in another non-interventional drug or device study or
        registry is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Vincenz Krankenhaus</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universistetssjukhus</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

